GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023 09:00 ET
|
GeoVax, Inc.
Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
August 29, 2023 09:00 ET
|
GeoVax, Inc.
Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Aug. 29, 2023 (GLOBE NEWSWIRE) --...
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
August 28, 2023 09:00 ET
|
GeoVax, Inc.
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
August 10, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months via NewMediaWire — GeoVax Labs, Inc....
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate Update
August 09, 2023 16:00 ET
|
GeoVax, Inc.
Progress and Promising Outlook for Gedeptin® and GEO-CM04S1; Phase 2 GEO-CM04S1; Clinical Trial Initiated for Patients with Chronic Lymphocytic Leukemia Company to Host Conference Call and Webcast...
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
July 26, 2023 09:00 ET
|
GeoVax, Inc.
GeoVax to Host Second Quarter 2023 Conference Call at 4:30 PM ET ATLANTA, GA, July 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Issuance of Ebola Vaccine Patent
July 24, 2023 09:00 ET
|
GeoVax, Inc.
Addressing Multiple Strains of Ebolavirus ATLANTA, GA, July 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
July 20, 2023 09:00 ET
|
GeoVax, Inc.
Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA, July 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
July 10, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
June 28, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...